glembatumumab vedotin also known antibodydrug conjugate adc targets cancer cells expressing transmembrane glycoprotein nmb gpnmb may us fda granted fast track designation treatment advanced refractory resistant gpnmbexpressing breast fully human monoclonal antibody glembatumumab linked monomethyl auristatin e mmaecitation needed uses valinecitrulline enzymecleavable linkage stable bloodstream antibody binds gpnmb cancer cells adc internalised linkage broken mmae released kill preclinical studies glembatumumab vedotin capable killing gpnmb expressing melanoma breast cancer cells inducing partial complete regression gpnmbexpressing tumors mouse glembatumumab vedotin development april celldex acquired curagen originally developed partnership curagen amgen using xenomouse technology licensed abgenix adc technology licensed seattle genetics celldex announced formed cooperative research development agreement nci sponsor two clinical trials uveal melanoma pediatric osteosarcoma phase ii clinical september phase clinical study started glembatumumab vedotin patients gpnmbexpressing breast cancer including triple negative breast cancercitation needed june phase iii clinical trials glembatumumab vedotin treatment advanced breast completed official study result posted preliminary results trials shown glembatumumab vedotin clinical activity promotes tumor shrinkage cancer patients whose tumors express gpnmb respond better glembatumumab longer progressionfree survival whose tumors express gpnmb breast accelerated approval phase ii clinical trial metric investigating glembatumumab vedotin versus capecitabine crossover allowed begun november expected enroll patients gpnmbexpressing metastatic triple negative breast cancer patients progressed receiving anthracyclines taxanes development adc discontinued april missing primary endpoint study failed help women toughtotreat metastatic triplenegative breast cancers tnbc stay alive progressionfree longer roche holding ags xeloda httpsenwikipediaorgwikiglembatumumabvedotin